Patricia Gallego

Patricia Gallego

Patricia Gallego PhD leads Airfinity’s COVID-19 analyst team, covering epidemiology, competitor and commercial intelligence across both treatments and vaccines. She has multiple years of experience in the biotechnology sector and a background in research at Imperial College London where she has published peer-reviewed papers on the relationship between chronic inflammation in Multiple Sclerosis and neurotransmission. As an excellent science communicator, Patricia has presented her research at international conferences and has given numerous talks to technical and non-specialist (public, MS patients, school children) audiences.

Patricia Gallego PhD leads Airfinity’s COVID-19 analyst team, covering epidemiology, competitor and commercial intelligence across both treatments and vaccines. She has multiple years of experience in the biotechnology sector and a background in research at Imperial College London where she has published peer-reviewed papers on the relationship between chronic inflammation in Multiple Sclerosis and neurotransmission. As an excellent science communicator, Patricia has presented her research at international conferences and has given numerous talks to technical and non-specialist (public, MS patients, school children) audiences.

Articles: Patricia Gallego

Vaccines Need to Stop the Spread of COVID or Protect against New Variants & Other Viruses to Disrupt Market & Reduce Healthcare Burden

Opinion / Airfinity’s Dr Patricia Gallego highlights the persistent threat that COVID-19 continues to present to patients and healthcare systems around the world and outlines the urgent need for more vaccine breakthroughs in 2023 to combat the “tripledemic” burden of COVID-19, flu and RSV.   2023 will be a pivotal year for RSV but to reduce the…

See more